- 2017 American Transplant Congress - Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…
- 2017 American Transplant Congress - Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.- Yale University, New Haven, CT Background: Studies in heart, lung, kidney, & liver transplantation (LT) indicate an increased negative impact of antibodies (Ab) to HLA on allograft outcome.Aim: To describe…
- 2017 American Transplant Congress - Can Pre-Treatment CDC Titres Predict Graft Outcomes in HLA Incompatible Transplants?Introduction: Complement Dependent Cytotoxic (CDC) (non-augmented) cross matching and Flow cytometric (FC) cross matching are two commonly used techniques to identify anti- Human Leucocyte Antigen…
- 2017 American Transplant Congress - HLA Class II Molecules Partner with TLR4 to Stimulate Endothelial Cell Activation and Proliferation.- Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA Background: Transplant recipients developing donor specific HLA antibodies (DSA) are at a higher risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the…
- 2017 American Transplant Congress - Anti-HLA I Antibody Enhances Endothelial Cell-Induced Polarization of Human Monocytes to M2a/c-Like Macrophages.HLA antibody (Ab)-mediated rejection (AMR) is often characterized by graft-infiltrating macrophages, which correlate with tissue fibrosis. Recent studies suggest they may mainly represent M2-polarized macrophages.…
- 2017 American Transplant Congress - A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.- 1U of Cincinnati, Cincinnati; 2Christ Hospital, Cincinnati Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…
- 2017 American Transplant Congress - Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.Background: Presence of anti-HLA donor specific antibodies (DSAs) has been associated with inferior kidney transplant outcomes. Identification of risk factors for de novo DSAs could…
- 2017 American Transplant Congress - Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients.- Nephrology and Hypertension, Stony Brook Medicine, Stony Brook, NY Background: The occurrence of anti-HLA de novo DSA (dnDSA) has been associated with the histological features of antibody-mediated rejection (ABMR) on kidney biopsy. The significance…
- 2017 American Transplant Congress - Positive Flow Crossmatch After Negative Virtual Crossmatch -A Single Center Experience.- Pathology and Lab Medicine, London Health Sciences Center, London, ON, Canada Aims: To determine causes of Flow Cytometry crossmatch (FCXM) after a negative virtual crossmatch (VirXM), even with sensitive solid-phase antibody assay and complete HLA typings…
- 2017 American Transplant Congress - Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.- Kidney Transplant, Cedars-Sinai Medical Center, LA, CA INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 47
- Next Page »
